Deucravacitinib, a TYK2 inhibitor, safety in psoriasis and psoriatic arthritis: What should a dermatologist know?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Deucravacitinib, a TYK2 inhibitor, safety in psoriasis and psoriatic arthritis: What should a dermatologist know?

Published:2023-03-21 Issue:2 Volume:2 Page:382-385
ISSN:2768-6566
Container-title:JEADV Clinical Practice
language:en
Short-container-title:JEADV Clinical Practice

Author:

Pereira Amaral Inês¹^ORCID,Antunes Joana¹²,Soares Ivânia¹,Pupo Correia Madalena¹^ORCID,Filipe Paulo¹²³

Affiliation:

1. Dermatology Department Centro Hospitalar Universitário Lisboa Norte EPE Lisbon Portugal

2. Dermatology University Clinic Faculdade de Medicina da Universidade de Lisboa Lisbon Portugal

3. Dermatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes Universidade de Lisboa Lisbon Portugal

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jvc2.132

Reference8 articles.

1. Deucravacitinib for the Treatment of Psoriatic Disease

2. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

3. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

4. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials

5. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP